Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Neuland Laboratories posts blockbuster FY26 performance

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint

Artemis Medicare Q4 FY26 revenue rises 16.4% to Rs. 27,923 lakh, net profit jumps 32.1%

The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year

Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%

With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit